A Natural Solution for California's Herds: African Catfish Peptides

California's cattle producers and agricultural communities are all too familiar with the rising challenge of antibiotic resistance, making common bacterial infections harder to treat in livestock. But imagine a future where we could tackle these infections with a natural, powerful alternative. Our research points to just that: antimicrobial peptides (AMPs) found in African catfish.

We're really excited about these peptides because African catfish thrive in pathogen-rich freshwater, naturally producing these robust immune compounds in their skin mucus as a defense. This natural origin makes them highly appealing alternatives to synthetic drugs.

Predicted Safety and Potent Action

One of the most compelling aspects of these AMPs is their predicted safety for mammals. Our initial computer analyses suggest that various catfish AMPs are generally recognized as safe (GRAS). We predict they'll be absorbed in the human intestine without causing liver, brain, or heart toxicity. Furthermore, lab tests on a promising peptide, NACAP-II, confirmed it was non-hemolytic, meaning it didn't damage rabbit red blood cells—a strong indicator of its potential safety for mammalian cells.

Beyond safety, these peptides demonstrate effectiveness against problematic bacteria. One study revealed NACAP-II's strong activity against Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia coli—a critical concern for both animal and human health due to its resistance to many common antibiotics. Another peptide, ACAP-IV, also showed antibacterial activity against E. coli and Staphylococcus aureus. We believe these AMPs work by directly disrupting bacterial cell membranes, a mechanism that makes it harder for bacteria to develop resistance compared to how they resist traditional antibiotics.

Page

Breeze™ Mat Rush

Lomandra longifolia 'LM300' Breeze on 20% of ETo in September 2018. Photo: SK Reid. After previously evaluating this plant in the full-sun field, where we noted uneven performance, trials staff were interested to see if the plant would perform better in this region when grown under 50% shade.
View Page
Page

Bella Donna Abelia

Abelia grandiflora Wevol Bella Donna in April 2018 before treatments began. Photo: SK Reid. Overall, we feel this cultivar of Abelia never reached its full potential in our trials, though several individuals did reach acceptable overall appearance ratings.
View Page
Page

BananAppeal® Small Anise Tree

Illicium parviflorum PIIIP-I BananAppeal in April 2018. Plants already showing incompatibility with our soil or climate conditions. Photo: SK Reid. Trials staff were excited to learn a new genus and family when we received a request to evaluate this cultivar.
View Page
Page

Harlow Carr Rose

Rosa Harlow Carr at first bloom in April 2016. (Before treatments began; 20% ET0.) Photo: SK Reid. This is a fragrant, pink David Austin shrub rose. Like so many English roses, it attained greater height and width in our region than advertised by the breeder.
View Page
Page

Bordeaux® Rose

Rosa Bordeaux in April 2016 with brilliant red blooms and dark glossy foliage. Photo: SK Reid. This shrub rose was a good performer overall, with no significant differences in growth between treatments.
View Page
Page

Lone Star® Rose

Rosa Lone Star in April 2016 full of blooms and buds. Photo: SK Reid. Lone Star is a yellow-flowered shrub rose that started its second year strong, but had foliar issues throughout the growing season.
View Page
Page

Coral Drift® Rose

Rosa Drift Coral in April with heavy show of blooms. Photo: SK Reid. One of three Drift roses in the trials this year, Coral, Pink, and Red, this one had perhaps the splashiest floral display but combined with the greatest susceptibility to powdery mildew.
View Page
Page

Red Drift® Rose

Rosa Drift Red in April 2016 in full bloom. Photo: SK Reid. Red Drift showed good disease resistance and good tolerance of the thrips damage common to all the roses grown in our field, flowering on and off from April to October (Table 11).
View Page